Global mRNA vaccine venture financing declines 82%
Venture financing for mRNA-based innovator vaccines saw an 82% decline from $510 million in 2023 to $90 million in 2025 year-to-date (YTD), new research shows.
In addition, the US Department of Health and Human Services’ (HHS) $500 million cut in grant support for mRNA vaccine projects announced in August 2025 has created uncertainty for biotech developers and may shift investor focus toward non-vaccine applications of mRNA technology, says pharma analytics company GlobalData.
Alison Labya, senior business fundamentals pharma analyst at GlobalData, commented: “The success of mRNA vaccines – notably Pfizer’s Comirnaty and Moderna’s Spikevax - against the COVID-19 pandemic fueled investor confidence, and spurred efforts to expand mRNA technology beyond vaccines into therapeutics across oncology and genetic disorders.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze